|Videos|July 6, 2021

The Importance of the Results of the Phase 3 Trial Assessing Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.

During the discussion, Kosiborod explained why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

The Importance of the Results of the Phase 3 Trial Assessing Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19

Related Content

Q&A: Pharmacists' Role in CKD Grows as Finerenone Eyes Label Expansion

Thoracic Radiotherapy Added to Atezolizumab Raises Fatal Toxicity Risk in ES-SCLC

FDA Approves First OTC Acetaminophen–Naproxen Combination for 12-Hour Pain Relief

The Weekly Dose: AHA Says Coffee Is Safe for Most, Wildfire Smoke Risks for Respiratory Patients, and New Options for Sleep Apnea, ROS1-Positive Lung Cancer

What Real-World Data Show About Moving Patients From Humira to Biosimilars

Latest CME

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Infectious Disease Day of Education 2026

Cyclosporiasis on the Rise: What Pharmacists Need to Know

The Educated Pharmacist - Weighing In: Translating Evidence to Practice — A Multidisciplinary Analysis of Obesity Pharmacotherapy Implementation and Team-Based Care

NEIAP Conference 2026

Innovations in Narcolepsy Treatment: Emerging Targets and Implications for Managed Care

NEIAP 2026 Annual Forum

PBMI 2026

Infectious Disease Day of Education 2026

New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Beyond the Nasal Passage: Managing Chronic Rhinosinusitis With Nasal Polyps With Biologics and Pharmacist-Led Approaches

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Advancing Chronic Kidney Disease Detection and Cardiovascular Risk Reduction in Complex Patients

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Advancing the Management of Hidradenitis Suppurativa: Emerging Therapies and Managed Care Strategies Across Patient Populations

Improving Outcomes in Fibrosing Interstitial Lung Diseases: Exploring Novel Mechanisms of Action and New Indications to Inform Clinical and Managed Care Decision-Making

Evolving Treatment Options in Plaque Psoriasis: Implications of Emerging TYK2 Inhibitors for Managed Care

New Treatments in Systemic Lupus Erythematosus to Advance Care: A Managed Care Focus on Nephritis

Looking at Patient-Centered Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Through a Value-Based Lens

Lymphoma Day of Education 2026

Shingles Vaccination: Opportunities for Pharmacist Interventions to Provide Patient Education

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Exploring Immunotherapy Strategies in Endometrial Cancer

Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

An American Journal of Managed Care Forum: Bridging Evidence and Access in Advanced Small Cell Lung Cancer

The Educated Pharmacist: Overcoming Clinical Inertia—An Interactive Case Workshop for Optimizing Insulin Use

Pharmacogenomics in Practice: Enhancing Patient Care Through Genetic Insights

Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care

Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

Two Targets, One Mission: Optimizing Bispecific Antibody Use in Non-Hodgkin Lymphoma

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Multidisciplinary Insights to Enhance Biomarker Testing Practices in Non-Small Cell Lung Cancer

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Minimizing Injection Burden: Anti-VEGF Innovation for Retinal Disease Management

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Managing Overactive Bladder in Older Adults: Challenges and Strategies for Long-Term Care

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations (Pharmacy Technician Credit)

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC

Payment for Pharmacist Services: 2025 Update

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

Translating KDIGO Updates and Clinical Evidence Into Managed Care Decision-Making in IgA Nephropathy

Expert Insights on the Horizon of HER2-Directed Therapy

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

Addressing the Burden of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: The Pharmacist's Contribution to Patient Care

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Lymphoma Day of Education 2026

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions